Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALF-5755 in Severe Acute Hepatitis and Acute Liver Failure
NCT01318525Phase 2Unknown
- Sponsor
- Alfact Innovation SAS
- Start
- Oct 2010
- Primary completion
- May 2012
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ALF-5755 in acute hepatitis, acute liver failure (ALF), sponsored by Alfact Innovation SAS. Status: unknown.
02
Drugs
ALF-5755
03
Conditions
acute hepatitisacute liver failure (ALF)
Beyond the preview
Go deeper on NCT01318525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01318525.